Christensen J H, Kristiansen J H
Aalborg Sygehus Nord, medicinsk endokrinologisk afdeling.
Ugeskr Laeger. 1992 Nov 16;154(47):3341-2.
Pamidronate (aminopropylidene diphosphonate, APD) is known to be an effective agent in lowering plasma calcium in cancer associated hypercalcaemia and in primary hyperparathyroidism. Combined therapy with pamidronate and calcitonin has proved efficient in the treatment of severe cancer-associated hypercalcaemia. A 66-year-old woman in hypercalcaemic crisis caused by primary hypreparathyroidism was successfully treated with this combined therapy. Albumin corrected plasma calcium was 5.26 mmol/l on arrival and the PTH level was very high. The combined therapy lowered the plasma calcium to normal and made it possible to perform elective parathyreoidectomy. A 5.8 g parathyroid adenoma was removed. It is recommended to consider combined therapy with pamidronate and calcitonin in the emergency management of hypercalcaemic crisis.
帕米膦酸盐(氨基亚丙基二膦酸盐,APD)已知是降低癌症相关性高钙血症和原发性甲状旁腺功能亢进症患者血浆钙水平的有效药物。帕米膦酸盐与降钙素联合治疗已被证明对治疗严重的癌症相关性高钙血症有效。一名因原发性甲状旁腺功能亢进症引发高钙血症危象的66岁女性,通过这种联合治疗获得了成功治愈。入院时经白蛋白校正后的血浆钙水平为5.26 mmol/L,甲状旁腺激素水平非常高。联合治疗使血浆钙水平降至正常,并使得择期甲状旁腺切除术得以进行。术中切除了一个5.8 g的甲状旁腺腺瘤。建议在高钙血症危象的紧急处理中考虑使用帕米膦酸盐与降钙素的联合治疗。